A next generation BCG vaccine moves forward
HM Dockrell - The Lancet Infectious Diseases, 2022 - thelancet.com
Comment www. thelancet. com/infection Vol 22 October 2022 1405 candidate TB vaccines
are in the development pipeline, including individual antigens delivered by viral vectors or …
are in the development pipeline, including individual antigens delivered by viral vectors or …
Is it time to abandon routine antibiotics for transperineal prostate biopsy?
O Bratt - The Lancet Infectious Diseases, 2022 - thelancet.com
In The Lancet Infectious Diseases, Maciej Jacewicz and colleagues report the first
randomised clinical trial evaluating whether prophylactic antibiotics are needed in …
randomised clinical trial evaluating whether prophylactic antibiotics are needed in …
Can We Use Administrative Data to Accurately Identify Patients Who Receive a Prostate Biopsy?
LT Lavallée, RH Breau, D Fergusson… - JCO Clinical Cancer …, 2018 - ascopubs.org
Purpose Administrative health data can be a valuable resource for health research. Because
these data are not collected for research purposes, it is imperative that the accuracy of codes …
these data are not collected for research purposes, it is imperative that the accuracy of codes …
[HTML][HTML] Time trends in prostate cancer screening in Swiss primary care (2010 to 2017)–A retrospective study
S Zechmann, S Di Gangi, V Kaplan, R Meier… - Plos one, 2019 - journals.plos.org
Introduction Following years of controversy regarding screening for prostate cancer using
prostate-specific antigen, evidence evolves towards a more restrained and preference …
prostate-specific antigen, evidence evolves towards a more restrained and preference …
Prostate Cancer: Management in Elderly Men Population in 2017
V Soulier, S Thach, N Mottet - Geriatric Oncology, 2020 - Springer
Prostate cancer is the most common cancer in elderly patients. Localized disease is treated
following almost the standard of younger patients. However, the treatment depends on …
following almost the standard of younger patients. However, the treatment depends on …
[HTML][HTML] Podium Session 1: Prostate Cancer June 24, 2018; 1030–1130
F Saad, M Hussain, K Fizazi, P Rathenborg, N Shore… - CUAJ, 2018 - ncbi.nlm.nih.gov
Methods Eligible men with M0 CRPC, PSA doubling time≤ 10 months and PSA≥ 2 ng/mL
at screening continued androgen–deprivation therapy (ADT) and were randomized 2: 1 to …
at screening continued androgen–deprivation therapy (ADT) and were randomized 2: 1 to …
[CITATION][C] Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования «Московский …
ВА Никонов, ЮЮ Петрунин, АК Александрова… - сора НЕ Зимина, д. б. н …, 2016